Quince Therapeutics Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Stock Information for Quince Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Quince Therapeutics Inc.

Quince Therapeutics to Participate at Investor Events in December 2025
Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
Quince Therapeutics Presents Data from Patient-Reported Walking Capacity in Children with Ataxia-Telangiectasia at 54th Child Neurology Society Annual Meeting
Quince Therapeutics Announces CPT: Pharmacometrics & Systems Pharmacology Publication of eDSP Population Pharmacokinetic Modeling Study
Quince Therapeutics to Host Virtual Investor Day on October 2, 2025
Quince Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.